Literature DB >> 24150054

eComment. Is surgery still worthwhile as compared to stereotactic ablative radiotherapy or CyberKnife in high-risk surgical patients with Stage I non-small-cell-lung cancer?

Paolo Scanagatta1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24150054      PMCID： PMC3805226          DOI： 10.1093/icvts/ivt400

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN： 1569-9285


× No keyword cloud information.
  5 in total

Review 1.  Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer?

Authors:  Sarah Mahmood; Haris Bilal; Corinne Faivre-Finn; Rajesh Shah
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-07-30

2.  Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery.

Authors:  John Varlotto; Achilles Fakiris; John Flickinger; Laura Medford-Davis; Adam Liss; Julia Shelkey; Chandra Belani; Jill DeLuca; Abram Recht; Neelabh Maheshwari; Robert Barriger; Nengliang Yao; Malcolm DeCamp
Journal:  Cancer       Date:  2013-04-19       Impact factor: 6.860

Review 3.  The CyberKnife radiosurgery system for lung cancer.

Authors:  Joost Jan Nuyttens; Marjan van de Pol
Journal:  Expert Rev Med Devices       Date:  2012-09       Impact factor: 3.166

Review 4.  Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy?

Authors:  Suresh Senan; Marinus A Paul; Frank J Lagerwaard
Journal:  Lancet Oncol       Date:  2013-06       Impact factor: 41.316

5.  CyberKnife with Tumor Tracking: An Effective Treatment for High-Risk Surgical Patients with Stage I Non-Small Cell Lung Cancer.

Authors:  Viola J Chen; Eric Oermann; Saloomeh Vahdat; Jennifer Rabin; Simeng Suy; Xia Yu; Sean P Collins; Deepa Subramaniam; Filip Banovac; Eric Anderson; Brian T Collins
Journal:  Front Oncol       Date:  2012-02-01       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.